Bariatric Surgery Impacts on Nonalcoholic Fatty Liver Disease

Bariatric surgery has emerged as a potent intervention for the management of nonalcoholic fatty liver disease (NAFLD), a condition closely linked to obesity and metabolic dysfunction. By achieving sustained weight loss, procedures such as Roux-en-Y gastric bypass and sleeve gastrectomy not only reduce hepatic steatosis but also ameliorate inflammatory activity and fibrosis. Improvements in insulin sensitivity, lipid metabolism and adipokine profiles further contribute to liver health. Histological assessments reveal that, within months to years after surgery, many patients experience resolution of nonalcoholic steatohepatitis (NASH) and regression of fibrosis. Beyond weight reduction, alterations in gut microbiota, bile-acid signalling and systemic inflammation are thought to mediate additional hepatic benefits. Nonetheless, some malabsorptive procedures may carry a risk of nutritional deficiencies and, in rare cases, progressive liver dysfunction. Preoperative evaluation and long-term follow-up are essential to optimise outcomes. Overall, bariatric surgery represents a transformative approach to the treatment of NAFLD, with implications for reducing morbidity, improving quality of life and attenuating the global burden of liver-related complications in obesity.

Research from Nature Portfolio

One longitudinal study employed paired liver biopsies and advanced histopathological techniques to document NAFLD regression after bariatric surgery. In a cohort of patients with an initial prevalence of fatty liver in half of participants, mean body mass index fell substantially over follow-up. Histological analysis demonstrated marked reductions in collagen deposition and inflammatory cell markers, while immunohistochemistry revealed diminished activation of hepatic stellate cells. These findings provide direct tissue-level evidence that surgical weight loss leads to fibrotic regression and decreased steatosis, reinforcing the role of bariatric procedures in reversing key features of NAFLD.

Bariatric Surgery Impacts on Nonalcoholic Fatty Liver Disease publication trend

The graph below shows the total number of articles in bariatric surgery impacts on nonalcoholic fatty liver disease across all publications each year (not limited to Nature Index journals).

Technical terms

Nonalcoholic fatty liver disease (NAFLD): A spectrum of liver disorders characterised by excess fat accumulation in hepatocytes in the absence of significant alcohol intake.

Nonalcoholic steatohepatitis (NASH): A progressive form of NAFLD marked by hepatocyte injury, inflammation and variable fibrosis, carrying a risk of cirrhosis.

Steatosis: Accumulation of lipid droplets within liver cells, representing the initial and reversible stage of NAFLD.

Fibrosis: Deposition of extracellular matrix and scar tissue in the liver, which may progress to cirrhosis if untreated.

Roux-en-Y gastric bypass (RYGB): A bariatric procedure that reduces stomach size and bypasses part of the small intestine to induce weight loss.

Sleeve gastrectomy (SG): A restrictive bariatric surgery that removes a portion of the stomach to limit food intake and promote weight reduction.

References

1. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocrine Disorders (2022).
2. Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversal—a Case Series. Obesity Surgery (2017).
3. Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. JAMA Network Open (2019).
4. Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review. Journal of Clinical Medicine (2021).
5. Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut–Liver Axis. Nutrients (2021).
6. Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. Scientific Reports (2020).
7. Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies. Journal of Clinical Medicine (2021).